The treatment of childhood and adolescent chronic myeloid leukaemia in Nigeria.

Yıl 2012, Cilt: 4 Sayı: 4, 1 - 5, 03.12.2012

Anthony Oyekunle , S Adelasoye Rahman Bolarinwa A Ayansanwo T Aladekomo A Mamman Muheez Durosinmi

Öz

Introduction: The introduction of the tyrosine kinase inhibitors (TKI) has significantly improved the overall survival of Nigerian patients with chronic myeloid leukemia (CML). However, there have been concerns that the outcome for children and adolescents may be sub-optimal.
Objectives: To determine the overall survival (OS) of childhood and adolescent CML patients in Nigeria.
Methods: We retrospectively examined our records from 2003 to 2011, and identified all Ph+ or BCR-ABL1+ CML patients a‰¤ 18 years at diagnosis, and retrieved their clinical, haematological and biochemical parameters. They received imatinib at 260-340 mg/m2/day. Statistical analysis was done using SPSS 17, and survival studies using the Kaplan-Meier technique.
Results: Of the 410 patients diagnosed, 14 (3.4%; male/female = 5/9) paediatric cases were recorded, with a median age of 16.5 (range, 11 - 18) years. At presentation, nine and five patients respectively were in chronic and accelerated phases. As at April 2012, seven patients are known to be alive, one lost to follow-up and six dead from progressive disease. Overall survival at 1 and 2 years were 90% and 79% respectively; while estimated median survival is 48.2 months (95%CI = 42.3 - 54.1).
Conclusions: Imatinib continues to deliver impressive survival outcomes in Nigerian patients with CML. As compared to our previously reported data comprising mostly of adults, this cohort seems to suggest that survival outcomes are comparable in paediatric CML cases.

Anahtar Kelimeler

chronic myeloid leukemia; imatinib; childhood; adolescent; Nigeria

Kaynakça

• Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 2000; 60(7):2049-55.
• Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome- positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004 November 1, 2004;104(9):2655-60. 3.
• Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean J Pediatr. 2011;54(3):111-6. 4.
• SEER Cancer Statistics Review 1975-2008 [database on the Internet]. National Cancer Institute. Bethesda, MD. 2011 [cited 2011]. Available from: http://seer.cancer.gov/csr/1975_2008/. 5.
• Suttorp M, Millot F. Treatment of Pediatric Chronic Myeloid Leukemia in the Year 2010: Use of Tyrosine Kinase Inhibitors and Stem-Cell Transplantation. Hematology. 2010 December 1, 2010;2010(1):368-76. 6.
• Shah NP. Loss of Response to Imatinib: Mechanisms and Management. Hematology. 2005 January 1, 2005;2005(1):183-7. 7.
• Oyekunle A, Klyuchnikov E, Ocheni S, Kroger N, Zander AR, Baccarani M, et al. Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Acta Haematologica. 2011;126(1):30-9. 8.
• Durosinmi MA, Faluyi JO, Oyekunle AA, Salawu L, Adediran IA, Akinola NO, et al. The use of Imatinib mesylate (Glivec) in Nigerian patients with chronic myeloid leukemia. Cellular Therapy and Transplantation. 2008;1(2):10.3205/ctt-2008-en-000027.01. 9.
• Swerdlow S, Campo E, Lee Harris N, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC press; 2008. 10.
• Simonsson B, Appelbaum F, et al. Evolving concepts in the
• recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-20. 11.
• Central Intelligence Agency. 2011 [cited November 2011]. Available
• https://www.cia.gov/library/publications/the-world
• factbook/geos/ni.html. from: 12.
• therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant. 2008;42(S2):S40-S6. 13.
• Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. 14.
• Liu Y, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006;2(2):95-102. 15.
• Ensinger CL, Haack T, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. Apr 12;19(4):556-68. 16.
• Quintás-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2011. 17.
• Management of Chronic Myeloid Leukemia in Childhood. Current Hematologic Malignancy Reports. 2012;7(2):116- 24. 18.
• OP, Oyelese AT, Durosinmi MA. Long-term follow-up of Nigerian patients with Philadelphia-positive chronic myeloid leukemia. AORTIC 2011: Entering the 21st Century for Cancer Control in Africa; November 2011; Cairo, Egypt: AORTIC; 2011.